Privacy Statement   Terms & Conditions   Sitemap  
  Diseases   Research   About us  
TBE Meningococcal Disease Influenza Smallpox
 
Prophylaxis

  Smallpox VIG (Vaccinia Immune Globulin)

Baxter also has a strategic partnership to provide Cangene’s Vaccinia Immune Globulin (C-VIG), a hyperimmune globulin used to treat rare but potentially severe adverse reactions to smallpox vaccination.

Vaccinia Immune Globulin (C-VIG) is a sterile solution of purified gamma globulin containing antibodies to the vaccinia virus.

C-VIG has been recently approved by the FDA. It is licensed for the treatment of postvaccinial complications such as eczema vaccinatum, vaccinia necrosum, severe generalised vaccinia, vaccinia infection of eyes, mouth or other sites.

The European Union Commission recommends access to VIG to supplement smallpox stockpiling programmes. In the US, the Centers for Disease Control and Prevention (CDC) are supplementing their smallpox stockpiling strategy through the stocking of Vaccinia Immune Globulin (C-VIG). Recommended stockpiling is at a rate of 1 dose of C-VIG per 10,000 doses of stockpiled vaccine.


 » Printversion

 
 
  » find


 

Baxter Receives Contract From National Health Service in United Kingdom to Produce Stockpile of H5N1 Flu Vaccine
» read more

Acambis submits US licence application for ACAM2000 smallpox vaccine
» read more

 
Baxter Vaccines Industriestrasse 67, A-1221 Wien, Tel: +43-1-20100,